(The 4th CIIE) Interview｜Senior Vice President of Johnson & Johnson: The Chinese market is an important pole of the global innovation landscape
China News Service, Shanghai, November 9th, title: Interview | Senior Vice President of Johnson & Johnson: The Chinese market is an important pole of the global innovation landscape
China News Agency reporter Wang Enbo
"Let the world's leading innovative medical technology benefit the Chinese people faster and better, and promote the innovation from China to the world." During the 4th CIIE, Song Weiqun, Senior Vice President of Johnson & Johnson and Chairman of China Region, expressed this His expectations.
Under the influence of multiple factors such as the aging population and the new crown epidemic, the Chinese people's demand for innovative medical products and services has become increasingly urgent.
As one of the largest exhibitors in the medical equipment and medicine and healthcare area of the CIIE, Johnson & Johnson's attention to the Chinese market is self-evident.
"The future development opportunities of China's medical industry are very rich." Song Weiqun said in an exclusive interview with a reporter from China News Agency. As China has established a moderately prosperous society in an all-round way, the income level of residents continues to rise, and the public's demand for high-quality medical services continues to rise. This is for medical care. The high-quality development of the health industry provides a strong impetus.
Based on this judgment, Johnson & Johnson set up a booth covering an area of nearly 1,000 square meters at this CIIE to showcase hundreds of innovative products, technologies and solutions covering the entire human life cycle of its medical equipment, pharmaceuticals, consumer products and all-view businesses. The program includes 7 world premieres, 3 Asian premieres and 60 Chinese debut products.
Among them, the Monarch digital surgery platform, the first in Asia, is one of Johnson & Johnson's most important products in this exhibition. It is the world's first digital surgery platform for non-incision transbronchial diagnosis and treatment of lung cancer.
Song Weiqun said that the incidence and mortality of lung cancer in China have been on the rise in recent years, and it will also account for the largest proportion of new cancers and the highest mortality rate in China in 2020.
Therefore, Johnson & Johnson looks forward to introducing the world's latest and greatest innovative products and solutions to China quickly to benefit more patients.
Speaking of participating in the CIIE for four consecutive years, Song Weiqun said that the CIIE is an important link that closely connects the Chinese market and global companies, which fully reflects the Chinese government’s continued expansion of opening up and its emphasis on “stabilizing foreign investment” and “attracting foreign investment”. .
Through the CIIE platform, many of Johnson & Johnson's internationally leading innovative products and medical solutions have been better displayed and promoted, as well as favorable policy support.
As the first multinational companies to enter the Chinese market after the reform and opening up, Johnson & Johnson has always been a beneficiary of this open dividend.
In 1985, Johnson & Johnson established Xi'an Janssen Pharmaceutical Co., Ltd. in China. After that, the company's medical equipment, consumer products and other businesses settled in the Chinese market.
In addition, China is also one of Johnson & Johnson's four global innovation centers and the location of the world's largest external innovation incubator.
For more than 30 years, Johnson & Johnson has not only witnessed its participation in the process of China's reform and opening up, but has also grown on the road of innovation along with the Chinese market.
The continuous advancement of China's medical reform in recent years is a notable example.
Song Weiqun noted that the regulatory authorities are continuing to speed up the review and approval of innovative medicines and devices, accelerate the entry of innovative products into the medical insurance catalog, actively encourage the development of commercial health insurance, and improve the accessibility and affordability of innovative products. The policies of the first pilot zone have rapidly introduced the world’s most advanced medical products and medicines to China to serve Chinese patients.
"China has become one of the fastest growing markets for Johnson & Johnson's global business, and it is also a key market for Johnson & Johnson's global'development + innovation' dual-engine strategy." Song Weiqun said that Johnson & Johnson is firmly optimistic about China's economic development prospects, and its investment in China is continuously expanding.
The company will continue to enhance China's status as the most important global business development engine, and work with partners from all walks of life to build China into a global innovation engine.
At present, China is the only market where Johnson & Johnson has “end-to-end” R&D capabilities in the three major business segments of medical equipment, pharmaceuticals, and consumer products, except for the United States. There are more than 700 scientists and engineers in China who are dedicated to local and oriented Global R&D work.
"The Chinese market is an important pole of the global innovation landscape." Song Weiqun said that Johnson & Johnson will enhance local R&D, innovation and high-end manufacturing capabilities, so that products and more production processes can be truly "made in China."
In the future, we will continue to use high-quality open platforms such as the China International Import Expo, as well as the innovation strength and policy environment of key regions such as the Yangtze River Delta and the Guangdong-Hong Kong-Macao Greater Bay Area to accelerate investment innovation capacity building and achievement transformation.
(over)